Patients with cystic fibrosis have a high carriage rate of non-toxigenic Clostridium difficile

Clinical Microbiology and Infection

Volumn 20, Issue 7, 2014, Pages

  Bauer, M P ^a   Farid, A ^a   Bakker, M ^b   Hoek, R A S ^b   Kuijper, E J ^a   van Dissel, J T ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Asymptomatic carriage; CFTR mutations; Clostridium difficile; Cystic fibrosis; PCR ribotypes

Indexed keywords

AGED; ARTICLE; BACTERIAL STRAIN; CASE CONTROL STUDY; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; CYSTIC FIBROSIS; FEMALE; HUMAN; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; ADULT; CLASSIFICATION; CLOSTRIDIUM INFECTIONS; COMPLICATION; GENETIC VARIABILITY; GENETICS; GENOTYPE; HETEROZYGOTE; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; PEPTOCLOSTRIDIUM DIFFICILE; RIBOTYPING; VERY ELDERLY; YOUNG ADULT;

CLOSTRIDIUM DIFFICILE;

BACTERIAL TOXIN;

ADULT; AGED; AGED, 80 AND OVER; BACTERIAL TOXINS; CARRIER STATE; CASE-CONTROL STUDIES; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CYSTIC FIBROSIS; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; MALE; MIDDLE AGED; RIBOTYPING; YOUNG ADULT;

EID: 84905018084     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12439     Document Type: Article

References (14)

1. Walker AS, Eyre DW, Wyllie DH et al. Characterisation of Clostridium difficile hospital ward-based transmission using extensive epidemiological data and molecular typing. PLoS Med 2012; 9: e1001172.
2. Wu TC, McCarthy VP, Gill VJ. Isolation rate and toxigenic potential of Clostridium difficile isolates from patients with cystic fibrosis. J Infect Dis 1983; 148: 176.
3. Peach SL, Borriello SP, Gaya H, Barclay FE, Welch AR. Asymptomatic carriage of Clostridium difficile in patients with cystic fibrosis. J Clin Pathol 1986; 39: 1013-1018.
4. Welkon CJ, Long SS, Thompson CM Jr, Gilligan PH. Clostridium difficile in patients with cystic fibrosis. Am J Dis Child 1985; 139: 805-808.
5. Paltansing S, van den Berg RJ, Guseinova RA, Visser CE, van der Vorm ER, Kuijper EJ. Characteristics and incidence of Clostridium difficile-associated disease in The Netherlands, 2005. Clin Microbiol Infect 2007; 13: 1058-1064.
6. Bidet P, Lalande V, Salauze B et al. Comparison of PCR-ribotyping, arbitrarily primed PCR, and pulsed-field gel electrophoresis for typing Clostridium difficile. J Clin Microbiol 2000; 38: 2484-2487.
7. Kato H, Kato N, Watanabe K et al. Identification of toxin A-negative, toxin B-positive Clostridium difficile by PCR. J Clin Microbiol 1998; 36: 2178-2182.
8. Stubbs S, Rupnik M, Gibert M, Brazier J, Duerden B, Popoff M. Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile. FEMS Microbiol Lett 2000; 186: 307-312.
9. O'Donnell LJ, Virjee J, Heaton KW. Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate. BMJ 1990; 300: 439-440.
10. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 613-619.
11. Wilson KH, Sheagren JN. Antagonism of toxigenic Clostridium difficile by nontoxigenic C. difficile. J Infect Dis 1983; 147: 733-736.
12. Natarajan M, Walk ST, Young VB, Aronoff DM. A clinical and epidemiological review of non-toxigenic Clostridium difficile. Anaerobe 2013; 22: 1-5.
13. Villano SA, Seiberling M, Tatarowicz W, Monnot-Chase E, Gerding DN. Evaluation of an oral suspension of VP20621, spores of nontoxigenic Clostridium difficile strain M3, in healthy subjects. Antimicrob Agents Chemother 2012; 56: 5224-5229.
14. Lynch SV, Goldfarb KC, Wild YK, Kong W, De Lisle RC, Brodie EL. Cystic fibrosis transmembrane conductance regulator knockout mice exhibit aberrant gastrointestinal microbiota. Gut Microbes 2013; 4: 41-47.